Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this descriptive study, researchers assessed the most common short-term side effects of anthracycline and taxane-based chemotherapy in 122 Moroccan women with localized breast cancer, documenting frequent systemic, gastrointestinal, dermatological, neurological, musculoskeletal, and ocular toxicities.

This study found that scalp cooling effectively reduces chemotherapy-induced hair loss, especially with taxane-based regimens, and recent U.S. trials support its safety, despite logistical and insurance challenges.

In this study, the Orbis PAXMAN® scalp cooling system showed effectiveness and good tolerability in preventing chemotherapy-induced hair loss in breast cancer patients, particularly those receiving anthracycline-free chemotherapy, though the presence of comorbidities was linked to a higher risk of severe alopecia.

This scoping review found that chemotherapy-induced alopecia in breast cancer patients, especially when using anthracycline- and taxane-based regimens, occurs at higher rates and with more persistence than historically reported.

In this study, researchers used a patient-reported outcome questionnaire to assess long-term adverse effects in breast cancer patients undergoing chemotherapy, finding persistent symptoms like neuropathy, dysgeusia, insomnia, and nail loss. Peripheral neuropathy was notably prolonged in those receiving anthracycline- and taxane-based regimens compared to docetaxel/cyclophosphamide.